^
    2d
    Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis. (PubMed, Oncologist)
    Many repotrectinib AEs, including neurological AEs secondary to TRK inhibition, were mitigated with appropriate management, including dose modification and/or pharmacologic intervention.
    Journal • Adverse events
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ROS1 fusion • ROS1 positive • NTRK positive • NTRK fusion
    |
    Augtyro (repotrectinib)
    2d
    Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Wen-zhao ZHONG
    New P2 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK fusion
    |
    Alecensa (alectinib) • Piqray (alpelisib)
    3d
    Individualized duration of adjuvant alectinib therapy and rechallenge efficacy in ALK-positive non-small cell lung cancer: a case report. (PubMed, Front Med (Lausanne))
    Further research is needed to validate these approaches in larger cohorts. Furthermore, the favorable response to alectinib rechallenge observed in this case suggests that rechallenge therapy may offer a potential value in managing post-adjuvant recurrence, which warrants further investigation.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK rearrangement
    |
    Alecensa (alectinib)
    3d
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=68, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2026 --> Jun 2030
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)
    4d
    Pleuritis Induced by Brigatinib During the Treatment of Non-Small Cell Lung Cancer. (PubMed, Respirol Case Rep)
    This case highlights that clinicians should consider drug-induced pleuritis when pleural effusion develops during brigatinib therapy, particularly when it is inconsistent with the disease progression. Dose reduction to as low as 30 mg/day may be a safe and effective therapeutic option for selected patients.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    Alunbrig (brigatinib)
    4d
    STRN::NTRK3-fused neoplasm with "monster cells" in the pelvis of a young adult female: expanding the clinicopathologic spectrum of NTRK-rearranged neoplasms. (PubMed, Virchows Arch)
    Entrectinib was administered, and an excellent response was observed. This case emphasizes the relevance of performing NGS in cases with unusual clinicopathological findings to identify potential treatment options. Importantly, the morphology deviated from the classic fibrosarcoma-like appearance described in most adult NTRK3-fused neoplasms and broadens the morphological spectrum in which these neoplasms should be considered.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • STRN (Striatin) • CD163 (CD163 Molecule) • CD34 (CD34 molecule) • CD68 (CD68 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase) • F13A1 (Coagulation Factor XIII A Chain)
    |
    NTRK fusion
    |
    Rozlytrek (entrectinib)
    4d
    Design, synthesis and biological evaluation of selective inhibitors against the L858R/T790 M/C797S mutant EGFR kinase based on the scaffold of brigatinib. (PubMed, Eur J Med Chem)
    Furthermore, cell cycle arrest assay, apoptosis induction assays, Western blot assay, colony formation inhibition assay, cell migration inhibition assays, tube formation assay, and docking analysis were carried out to study the action mechanism of compound 8c. All these results indicated that compound 8c has the potential for further evaluation of in vivo efficacy and druggability.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR T790M
    |
    Alunbrig (brigatinib)
    4d
    A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Pfizer
    New trial • Real-world evidence
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK rearrangement
    |
    Lorbrena (lorlatinib)
    4d
    ALINA: A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=257, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Nov 2026 --> Nov 2031
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    cisplatin • carboplatin • gemcitabine • Alecensa (alectinib) • pemetrexed • vinorelbine tartrate
    5d
    Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Aug 2026 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    Lorbrena (lorlatinib)
    7d
    BO43249: A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status (2024-511239-91-00)
    P1/2, N=54, Recruiting, F. Hoffmann-La Roche AG | Phase classification: P2/3 --> P1/2
    Phase classification
    |
    ALK fusion
    |
    cisplatin • carboplatin • Alecensa (alectinib) • pemetrexed
    8d
    Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, China Medical University Hospital
    New P1/2 trial
    |
    ALK (Anaplastic lymphoma kinase)
    |
    Xalkori (crizotinib) • Alecensa (alectinib)